Agriculture
Global Live Brucellosis Vaccine Market Outlook, In‑Depth Analysis & Forecast to 2031
- Oct 04, 25
- ID: 537022
- Pages: 180
- Figures: 173
- Views: 3
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Live Brucellosis Vaccine market, seamlessly integrating production capacity and sales performance across the value chain. It analyzes historical production, revenue, and sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—capacity, sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
CZ Vaccines
MSD
Ceva
Colorado Serum
Tecnovax
Syva
Shchelkovo Biocombinat
Jinyu Baoling
Biovet
CAVAC
VETAL
Indian Immunologicals
Dollvet
Hester Biosciences
Qilu Animal Health
Auleon Biologicals
Segment by Type
Strain RB-51
Strain S19
Strain S2
Strain A19
Strain Rev. I
Segment by Application
Cattle
Sheep
Pig
Others
Production by Region
North America
Europe
China
Japan
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Live Brucellosis Vaccine study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Maps global production capacity, utilization, and market share (2020–2031), identifies efficient hubs, reveals regulatory/trade policy impacts and bottlenecks.
Chapter 4: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 5: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 6: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 7: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 8: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 9: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 10: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 11: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 12: Profiles manufacturers in depth—details product specs, capacity, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 13: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint and technology, cost drivers, plus downstream channels and distributor roles.
Chapter 14: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 7–11) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 13) and customers (Chapter 6) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 4 and 12).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 13 and 14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Live Brucellosis Vaccine market, seamlessly integrating production capacity and sales performance across the value chain. It analyzes historical production, revenue, and sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—capacity, sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
CZ Vaccines
MSD
Ceva
Colorado Serum
Tecnovax
Syva
Shchelkovo Biocombinat
Jinyu Baoling
Biovet
CAVAC
VETAL
Indian Immunologicals
Dollvet
Hester Biosciences
Qilu Animal Health
Auleon Biologicals
Segment by Type
Strain RB-51
Strain S19
Strain S2
Strain A19
Strain Rev. I
Segment by Application
Cattle
Sheep
Pig
Others
Production by Region
North America
Europe
China
Japan
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Live Brucellosis Vaccine study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Maps global production capacity, utilization, and market share (2020–2031), identifies efficient hubs, reveals regulatory/trade policy impacts and bottlenecks.
Chapter 4: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 5: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 6: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 7: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 8: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 9: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 10: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 11: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 12: Profiles manufacturers in depth—details product specs, capacity, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 13: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint and technology, cost drivers, plus downstream channels and distributor roles.
Chapter 14: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 7–11) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 13) and customers (Chapter 6) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 4 and 12).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 13 and 14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Live Brucellosis Vaccine: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Live Brucellosis Vaccine Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Strain RB-51
1.2.3 Strain S19
1.2.4 Strain S2
1.2.5 Strain A19
1.2.6 Strain Rev. I
1.3 Market Segmentation by Application
1.3.1 Global Live Brucellosis Vaccine Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Cattle
1.3.3 Sheep
1.3.4 Pig
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Live Brucellosis Vaccine Revenue Estimates and Forecasts 2020-2031
2.2 Global Live Brucellosis Vaccine Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Live Brucellosis Vaccine Sales Estimates and Forecasts 2020-2031
2.4 Global Live Brucellosis Vaccine Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Global Production Analysis
3.1 Global Live Brucellosis Vaccine Production Capacity and Utilization Rates (2020–2031)
3.2 Regional Production: Comparative Analysis (2020 VS 2024 VS 2031)
3.3 Regional Production Dynamics
3.3.1 Historic Production by Region (2020-2025)
3.3.2 Forecasted Production by Region (2026-2031)
3.3.3 Production Market Share by Region (2020-2031)
3.3.4 Regulatory and Trade Policy Impact on Production
3.3.5 Production Capacity Enablers and Constraints
3.4 Key Regional Production Hubs
3.4.1 North America
3.4.2 Europe
3.4.3 China
3.4.4 Japan
4 Competition by Manufacturers
4.1 Global Live Brucellosis Vaccine Sales by Manufacturers
4.1.1 Global Sales Volume by Manufacturers (2020-2025)
4.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
4.2 Global Live Brucellosis Vaccine Manufacturer Revenue Rankings and Tiers
4.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
4.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
4.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
4.3 Manufacturer Profitability Profiles and Pricing Strategies
4.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
4.3.2 Manufacturer-Level Price Trends (2020-2025)
4.4 Key Manufacturers Manufacturing Base and Headquarters
4.5 Main Product Type Market Size by Manufacturers
4.5.1 Strain RB-51 Market Size by Manufacturers
4.5.2 Strain S19 Market Size by Manufacturers
4.5.3 Strain S2 Market Size by Manufacturers
4.5.4 Strain A19 Market Size by Manufacturers
4.5.5 Strain Rev. I Market Size by Manufacturers
4.6 Global Live Brucellosis Vaccine Market Concentration and Dynamics
4.6.1 Global Market Concentration (CR5 and HHI)
4.6.2 Entrant/Exit Impact Analysis
4.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
5 Global Product Segmentation Analysis
5.1 Global Live Brucellosis Vaccine Sales Performance by Type
5.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
5.1.2 Global Sales Market Share by Type (2020-2031)
5.2 Global Live Brucellosis Vaccine Revenue Trends by Type
5.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
5.2.2 Global Revenue Market Share by Type (2020-2031)
5.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
5.4 Product Technology Differentiation
5.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
5.5.1 High-Growth Niches and Adoption Drivers
5.5.2 Profitability Hotspots and Cost Drivers
5.5.3 Substitution Threats
6 Global Downstream Application Analysis
6.1 Global Live Brucellosis Vaccine Sales by Application
6.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
6.1.2 Global Sales Market Share by Application (2020-2031)
6.1.3 High-Growth Application Identification
6.1.4 Emerging Application Case Studies
6.2 Global Live Brucellosis Vaccine Revenue by Application
6.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
6.2.2 Revenue Market Share by Application (2020-2031)
6.3 Global Pricing Dynamics by Application (2020-2031)
6.4 Downstream Customer Analysis
6.4.1 Top Customers by Region
6.4.2 Top Customers by Application
7 North America
7.1 North America Sales Volume and Revenue (2020-2031)
7.2 North America Key Manufacturers Sales Revenue in 2024
7.3 North America Live Brucellosis Vaccine Sales and Revenue by Type (2020-2031)
7.4 North America Live Brucellosis Vaccine Sales and Revenue by Application (2020-2031)
7.5 North America Growth Accelerators and Market Barriers
7.6 North America Live Brucellosis Vaccine Market Size by Country
7.6.1 North America Revenue by Country
7.6.2 North America Sales Trends by Country
7.6.3 US
7.6.4 Canada
7.6.5 Mexico
8 Europe
8.1 Europe Sales Volume and Revenue (2020-2031)
8.2 Europe Key Manufacturers Sales Revenue in 2024
8.3 Europe Live Brucellosis Vaccine Sales and Revenue by Type (2020-2031)
8.4 Europe Live Brucellosis Vaccine Sales and Revenue by Application (2020-2031)
8.5 Europe Growth Accelerators and Market Barriers
8.6 Europe Live Brucellosis Vaccine Market Size by Country
8.6.1 Europe Revenue by Country
8.6.2 Europe Sales Trends by Country
8.6.3 Germany
8.6.4 France
8.6.5 U.K.
8.6.6 Italy
8.6.7 Russia
9 Asia-Pacific
9.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
9.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
9.3 Asia-Pacific Live Brucellosis Vaccine Sales and Revenue by Type (2020-2031)
9.4 Asia-Pacific Live Brucellosis Vaccine Sales and Revenue by Application (2020-2031)
9.5 Asia-Pacific Live Brucellosis Vaccine Market Size by Region
9.5.1 Asia-Pacific Revenue by Region
9.5.2 Asia-Pacific Sales Trends by Region
9.6 Asia-Pacific Growth Accelerators and Market Barriers
9.7 Southeast Asia
9.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
9.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand
9.8 China
9.9 Japan
9.10 South Korea
9.11 China Taiwan
9.12 India
10 Central and South America
10.1 Central and South America Sales Volume and Revenue (2020-2031)
10.2 Central and South America Key Manufacturers Sales Revenue in 2024
10.3 Central and South America Live Brucellosis Vaccine Sales and Revenue by Type (2020-2031)
10.4 Central and South America Live Brucellosis Vaccine Sales and Revenue by Application (2020-2031)
10.5 Central and South America Investment Opportunities and Key Challenges
10.6 Central and South America Live Brucellosis Vaccine Market Size by Country
10.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 Brazil
10.6.3 Argentina
11 Middle East and Africa
11.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
11.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
11.3 Middle East and Africa Live Brucellosis Vaccine Sales and Revenue by Type (2020-2031)
11.4 Middle East and Africa Live Brucellosis Vaccine Sales and Revenue by Application (2020-2031)
11.5 Middle East and Africa Investment Opportunities and Key Challenges
11.6 Middle East and Africa Live Brucellosis Vaccine Market Size by Country
11.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
11.6.2 GCC Countries
11.6.3 Turkey
11.6.4 Egypt
11.6.5 South Africa
12 Corporate Profile
12.1 CZ Vaccines
12.1.1 CZ Vaccines Corporation Information
12.1.2 CZ Vaccines Business Overview
12.1.3 CZ Vaccines Live Brucellosis Vaccine Product Models, Descriptions and Specifications
12.1.4 CZ Vaccines Live Brucellosis Vaccine Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.1.5 CZ Vaccines Live Brucellosis Vaccine Sales by Product in 2024
12.1.6 CZ Vaccines Live Brucellosis Vaccine Sales by Application in 2024
12.1.7 CZ Vaccines Live Brucellosis Vaccine Sales by Geographic Area in 2024
12.1.8 CZ Vaccines Live Brucellosis Vaccine SWOT Analysis
12.1.9 CZ Vaccines Recent Developments
12.2 MSD
12.2.1 MSD Corporation Information
12.2.2 MSD Business Overview
12.2.3 MSD Live Brucellosis Vaccine Product Models, Descriptions and Specifications
12.2.4 MSD Live Brucellosis Vaccine Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.2.5 MSD Live Brucellosis Vaccine Sales by Product in 2024
12.2.6 MSD Live Brucellosis Vaccine Sales by Application in 2024
12.2.7 MSD Live Brucellosis Vaccine Sales by Geographic Area in 2024
12.2.8 MSD Live Brucellosis Vaccine SWOT Analysis
12.2.9 MSD Recent Developments
12.3 Ceva
12.3.1 Ceva Corporation Information
12.3.2 Ceva Business Overview
12.3.3 Ceva Live Brucellosis Vaccine Product Models, Descriptions and Specifications
12.3.4 Ceva Live Brucellosis Vaccine Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.3.5 Ceva Live Brucellosis Vaccine Sales by Product in 2024
12.3.6 Ceva Live Brucellosis Vaccine Sales by Application in 2024
12.3.7 Ceva Live Brucellosis Vaccine Sales by Geographic Area in 2024
12.3.8 Ceva Live Brucellosis Vaccine SWOT Analysis
12.3.9 Ceva Recent Developments
12.4 Colorado Serum
12.4.1 Colorado Serum Corporation Information
12.4.2 Colorado Serum Business Overview
12.4.3 Colorado Serum Live Brucellosis Vaccine Product Models, Descriptions and Specifications
12.4.4 Colorado Serum Live Brucellosis Vaccine Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.4.5 Colorado Serum Live Brucellosis Vaccine Sales by Product in 2024
12.4.6 Colorado Serum Live Brucellosis Vaccine Sales by Application in 2024
12.4.7 Colorado Serum Live Brucellosis Vaccine Sales by Geographic Area in 2024
12.4.8 Colorado Serum Live Brucellosis Vaccine SWOT Analysis
12.4.9 Colorado Serum Recent Developments
12.5 Tecnovax
12.5.1 Tecnovax Corporation Information
12.5.2 Tecnovax Business Overview
12.5.3 Tecnovax Live Brucellosis Vaccine Product Models, Descriptions and Specifications
12.5.4 Tecnovax Live Brucellosis Vaccine Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.5.5 Tecnovax Live Brucellosis Vaccine Sales by Product in 2024
12.5.6 Tecnovax Live Brucellosis Vaccine Sales by Application in 2024
12.5.7 Tecnovax Live Brucellosis Vaccine Sales by Geographic Area in 2024
12.5.8 Tecnovax Live Brucellosis Vaccine SWOT Analysis
12.5.9 Tecnovax Recent Developments
12.6 Syva
12.6.1 Syva Corporation Information
12.6.2 Syva Business Overview
12.6.3 Syva Live Brucellosis Vaccine Product Models, Descriptions and Specifications
12.6.4 Syva Live Brucellosis Vaccine Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.6.5 Syva Recent Developments
12.7 Shchelkovo Biocombinat
12.7.1 Shchelkovo Biocombinat Corporation Information
12.7.2 Shchelkovo Biocombinat Business Overview
12.7.3 Shchelkovo Biocombinat Live Brucellosis Vaccine Product Models, Descriptions and Specifications
12.7.4 Shchelkovo Biocombinat Live Brucellosis Vaccine Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.7.5 Shchelkovo Biocombinat Recent Developments
12.8 Jinyu Baoling
12.8.1 Jinyu Baoling Corporation Information
12.8.2 Jinyu Baoling Business Overview
12.8.3 Jinyu Baoling Live Brucellosis Vaccine Product Models, Descriptions and Specifications
12.8.4 Jinyu Baoling Live Brucellosis Vaccine Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.8.5 Jinyu Baoling Recent Developments
12.9 Biovet
12.9.1 Biovet Corporation Information
12.9.2 Biovet Business Overview
12.9.3 Biovet Live Brucellosis Vaccine Product Models, Descriptions and Specifications
12.9.4 Biovet Live Brucellosis Vaccine Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.9.5 Biovet Recent Developments
12.10 CAVAC
12.10.1 CAVAC Corporation Information
12.10.2 CAVAC Business Overview
12.10.3 CAVAC Live Brucellosis Vaccine Product Models, Descriptions and Specifications
12.10.4 CAVAC Live Brucellosis Vaccine Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.10.5 CAVAC Recent Developments
12.11 VETAL
12.11.1 VETAL Corporation Information
12.11.2 VETAL Business Overview
12.11.3 VETAL Live Brucellosis Vaccine Product Models, Descriptions and Specifications
12.11.4 VETAL Live Brucellosis Vaccine Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.11.5 VETAL Recent Developments
12.12 Indian Immunologicals
12.12.1 Indian Immunologicals Corporation Information
12.12.2 Indian Immunologicals Business Overview
12.12.3 Indian Immunologicals Live Brucellosis Vaccine Product Models, Descriptions and Specifications
12.12.4 Indian Immunologicals Live Brucellosis Vaccine Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.12.5 Indian Immunologicals Recent Developments
12.13 Dollvet
12.13.1 Dollvet Corporation Information
12.13.2 Dollvet Business Overview
12.13.3 Dollvet Live Brucellosis Vaccine Product Models, Descriptions and Specifications
12.13.4 Dollvet Live Brucellosis Vaccine Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.13.5 Dollvet Recent Developments
12.14 Hester Biosciences
12.14.1 Hester Biosciences Corporation Information
12.14.2 Hester Biosciences Business Overview
12.14.3 Hester Biosciences Live Brucellosis Vaccine Product Models, Descriptions and Specifications
12.14.4 Hester Biosciences Live Brucellosis Vaccine Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.14.5 Hester Biosciences Recent Developments
12.15 Qilu Animal Health
12.15.1 Qilu Animal Health Corporation Information
12.15.2 Qilu Animal Health Business Overview
12.15.3 Qilu Animal Health Live Brucellosis Vaccine Product Models, Descriptions and Specifications
12.15.4 Qilu Animal Health Live Brucellosis Vaccine Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.15.5 Qilu Animal Health Recent Developments
12.16 Auleon Biologicals
12.16.1 Auleon Biologicals Corporation Information
12.16.2 Auleon Biologicals Business Overview
12.16.3 Auleon Biologicals Live Brucellosis Vaccine Product Models, Descriptions and Specifications
12.16.4 Auleon Biologicals Live Brucellosis Vaccine Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.16.5 Auleon Biologicals Recent Developments
13 Value Chain and Supply-Chain Analysis
13.1 Live Brucellosis Vaccine Industry Chain
13.2 Live Brucellosis Vaccine Upstream Materials Analysis
13.2.1 Raw Materials
13.2.2 Key Suppliers Market Share & Risk Assessment
13.3 Live Brucellosis Vaccine Integrated Production Analysis
13.3.1 Manufacturing Footprint Analysis
13.3.2 Production Technology Overview
13.3.3 Regional Cost Drivers
13.4 Live Brucellosis Vaccine Sales Channels and Distribution Networks
13.4.1 Sales Channels
13.4.2 Distributors
14 Live Brucellosis Vaccine Market Dynamics
14.1 Industry Trends and Evolution
14.2 Market Growth Drivers and Emerging Opportunities
14.3 Market Challenges, Risks, and Restraints
15 Key Findings in the Global Live Brucellosis Vaccine Study
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.1.1 Research Programs/Design
16.1.1.2 Market Size Estimation
16.1.1.3 Market Breakdown and Data Triangulation
16.1.2 Data Source
16.1.2.1 Secondary Sources
16.1.2.2 Primary Sources
16.2 Author Details
1.1 Introduction to Live Brucellosis Vaccine: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Live Brucellosis Vaccine Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Strain RB-51
1.2.3 Strain S19
1.2.4 Strain S2
1.2.5 Strain A19
1.2.6 Strain Rev. I
1.3 Market Segmentation by Application
1.3.1 Global Live Brucellosis Vaccine Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Cattle
1.3.3 Sheep
1.3.4 Pig
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Live Brucellosis Vaccine Revenue Estimates and Forecasts 2020-2031
2.2 Global Live Brucellosis Vaccine Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Live Brucellosis Vaccine Sales Estimates and Forecasts 2020-2031
2.4 Global Live Brucellosis Vaccine Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Global Production Analysis
3.1 Global Live Brucellosis Vaccine Production Capacity and Utilization Rates (2020–2031)
3.2 Regional Production: Comparative Analysis (2020 VS 2024 VS 2031)
3.3 Regional Production Dynamics
3.3.1 Historic Production by Region (2020-2025)
3.3.2 Forecasted Production by Region (2026-2031)
3.3.3 Production Market Share by Region (2020-2031)
3.3.4 Regulatory and Trade Policy Impact on Production
3.3.5 Production Capacity Enablers and Constraints
3.4 Key Regional Production Hubs
3.4.1 North America
3.4.2 Europe
3.4.3 China
3.4.4 Japan
4 Competition by Manufacturers
4.1 Global Live Brucellosis Vaccine Sales by Manufacturers
4.1.1 Global Sales Volume by Manufacturers (2020-2025)
4.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
4.2 Global Live Brucellosis Vaccine Manufacturer Revenue Rankings and Tiers
4.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
4.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
4.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
4.3 Manufacturer Profitability Profiles and Pricing Strategies
4.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
4.3.2 Manufacturer-Level Price Trends (2020-2025)
4.4 Key Manufacturers Manufacturing Base and Headquarters
4.5 Main Product Type Market Size by Manufacturers
4.5.1 Strain RB-51 Market Size by Manufacturers
4.5.2 Strain S19 Market Size by Manufacturers
4.5.3 Strain S2 Market Size by Manufacturers
4.5.4 Strain A19 Market Size by Manufacturers
4.5.5 Strain Rev. I Market Size by Manufacturers
4.6 Global Live Brucellosis Vaccine Market Concentration and Dynamics
4.6.1 Global Market Concentration (CR5 and HHI)
4.6.2 Entrant/Exit Impact Analysis
4.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
5 Global Product Segmentation Analysis
5.1 Global Live Brucellosis Vaccine Sales Performance by Type
5.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
5.1.2 Global Sales Market Share by Type (2020-2031)
5.2 Global Live Brucellosis Vaccine Revenue Trends by Type
5.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
5.2.2 Global Revenue Market Share by Type (2020-2031)
5.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
5.4 Product Technology Differentiation
5.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
5.5.1 High-Growth Niches and Adoption Drivers
5.5.2 Profitability Hotspots and Cost Drivers
5.5.3 Substitution Threats
6 Global Downstream Application Analysis
6.1 Global Live Brucellosis Vaccine Sales by Application
6.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
6.1.2 Global Sales Market Share by Application (2020-2031)
6.1.3 High-Growth Application Identification
6.1.4 Emerging Application Case Studies
6.2 Global Live Brucellosis Vaccine Revenue by Application
6.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
6.2.2 Revenue Market Share by Application (2020-2031)
6.3 Global Pricing Dynamics by Application (2020-2031)
6.4 Downstream Customer Analysis
6.4.1 Top Customers by Region
6.4.2 Top Customers by Application
7 North America
7.1 North America Sales Volume and Revenue (2020-2031)
7.2 North America Key Manufacturers Sales Revenue in 2024
7.3 North America Live Brucellosis Vaccine Sales and Revenue by Type (2020-2031)
7.4 North America Live Brucellosis Vaccine Sales and Revenue by Application (2020-2031)
7.5 North America Growth Accelerators and Market Barriers
7.6 North America Live Brucellosis Vaccine Market Size by Country
7.6.1 North America Revenue by Country
7.6.2 North America Sales Trends by Country
7.6.3 US
7.6.4 Canada
7.6.5 Mexico
8 Europe
8.1 Europe Sales Volume and Revenue (2020-2031)
8.2 Europe Key Manufacturers Sales Revenue in 2024
8.3 Europe Live Brucellosis Vaccine Sales and Revenue by Type (2020-2031)
8.4 Europe Live Brucellosis Vaccine Sales and Revenue by Application (2020-2031)
8.5 Europe Growth Accelerators and Market Barriers
8.6 Europe Live Brucellosis Vaccine Market Size by Country
8.6.1 Europe Revenue by Country
8.6.2 Europe Sales Trends by Country
8.6.3 Germany
8.6.4 France
8.6.5 U.K.
8.6.6 Italy
8.6.7 Russia
9 Asia-Pacific
9.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
9.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
9.3 Asia-Pacific Live Brucellosis Vaccine Sales and Revenue by Type (2020-2031)
9.4 Asia-Pacific Live Brucellosis Vaccine Sales and Revenue by Application (2020-2031)
9.5 Asia-Pacific Live Brucellosis Vaccine Market Size by Region
9.5.1 Asia-Pacific Revenue by Region
9.5.2 Asia-Pacific Sales Trends by Region
9.6 Asia-Pacific Growth Accelerators and Market Barriers
9.7 Southeast Asia
9.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
9.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand
9.8 China
9.9 Japan
9.10 South Korea
9.11 China Taiwan
9.12 India
10 Central and South America
10.1 Central and South America Sales Volume and Revenue (2020-2031)
10.2 Central and South America Key Manufacturers Sales Revenue in 2024
10.3 Central and South America Live Brucellosis Vaccine Sales and Revenue by Type (2020-2031)
10.4 Central and South America Live Brucellosis Vaccine Sales and Revenue by Application (2020-2031)
10.5 Central and South America Investment Opportunities and Key Challenges
10.6 Central and South America Live Brucellosis Vaccine Market Size by Country
10.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 Brazil
10.6.3 Argentina
11 Middle East and Africa
11.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
11.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
11.3 Middle East and Africa Live Brucellosis Vaccine Sales and Revenue by Type (2020-2031)
11.4 Middle East and Africa Live Brucellosis Vaccine Sales and Revenue by Application (2020-2031)
11.5 Middle East and Africa Investment Opportunities and Key Challenges
11.6 Middle East and Africa Live Brucellosis Vaccine Market Size by Country
11.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
11.6.2 GCC Countries
11.6.3 Turkey
11.6.4 Egypt
11.6.5 South Africa
12 Corporate Profile
12.1 CZ Vaccines
12.1.1 CZ Vaccines Corporation Information
12.1.2 CZ Vaccines Business Overview
12.1.3 CZ Vaccines Live Brucellosis Vaccine Product Models, Descriptions and Specifications
12.1.4 CZ Vaccines Live Brucellosis Vaccine Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.1.5 CZ Vaccines Live Brucellosis Vaccine Sales by Product in 2024
12.1.6 CZ Vaccines Live Brucellosis Vaccine Sales by Application in 2024
12.1.7 CZ Vaccines Live Brucellosis Vaccine Sales by Geographic Area in 2024
12.1.8 CZ Vaccines Live Brucellosis Vaccine SWOT Analysis
12.1.9 CZ Vaccines Recent Developments
12.2 MSD
12.2.1 MSD Corporation Information
12.2.2 MSD Business Overview
12.2.3 MSD Live Brucellosis Vaccine Product Models, Descriptions and Specifications
12.2.4 MSD Live Brucellosis Vaccine Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.2.5 MSD Live Brucellosis Vaccine Sales by Product in 2024
12.2.6 MSD Live Brucellosis Vaccine Sales by Application in 2024
12.2.7 MSD Live Brucellosis Vaccine Sales by Geographic Area in 2024
12.2.8 MSD Live Brucellosis Vaccine SWOT Analysis
12.2.9 MSD Recent Developments
12.3 Ceva
12.3.1 Ceva Corporation Information
12.3.2 Ceva Business Overview
12.3.3 Ceva Live Brucellosis Vaccine Product Models, Descriptions and Specifications
12.3.4 Ceva Live Brucellosis Vaccine Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.3.5 Ceva Live Brucellosis Vaccine Sales by Product in 2024
12.3.6 Ceva Live Brucellosis Vaccine Sales by Application in 2024
12.3.7 Ceva Live Brucellosis Vaccine Sales by Geographic Area in 2024
12.3.8 Ceva Live Brucellosis Vaccine SWOT Analysis
12.3.9 Ceva Recent Developments
12.4 Colorado Serum
12.4.1 Colorado Serum Corporation Information
12.4.2 Colorado Serum Business Overview
12.4.3 Colorado Serum Live Brucellosis Vaccine Product Models, Descriptions and Specifications
12.4.4 Colorado Serum Live Brucellosis Vaccine Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.4.5 Colorado Serum Live Brucellosis Vaccine Sales by Product in 2024
12.4.6 Colorado Serum Live Brucellosis Vaccine Sales by Application in 2024
12.4.7 Colorado Serum Live Brucellosis Vaccine Sales by Geographic Area in 2024
12.4.8 Colorado Serum Live Brucellosis Vaccine SWOT Analysis
12.4.9 Colorado Serum Recent Developments
12.5 Tecnovax
12.5.1 Tecnovax Corporation Information
12.5.2 Tecnovax Business Overview
12.5.3 Tecnovax Live Brucellosis Vaccine Product Models, Descriptions and Specifications
12.5.4 Tecnovax Live Brucellosis Vaccine Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.5.5 Tecnovax Live Brucellosis Vaccine Sales by Product in 2024
12.5.6 Tecnovax Live Brucellosis Vaccine Sales by Application in 2024
12.5.7 Tecnovax Live Brucellosis Vaccine Sales by Geographic Area in 2024
12.5.8 Tecnovax Live Brucellosis Vaccine SWOT Analysis
12.5.9 Tecnovax Recent Developments
12.6 Syva
12.6.1 Syva Corporation Information
12.6.2 Syva Business Overview
12.6.3 Syva Live Brucellosis Vaccine Product Models, Descriptions and Specifications
12.6.4 Syva Live Brucellosis Vaccine Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.6.5 Syva Recent Developments
12.7 Shchelkovo Biocombinat
12.7.1 Shchelkovo Biocombinat Corporation Information
12.7.2 Shchelkovo Biocombinat Business Overview
12.7.3 Shchelkovo Biocombinat Live Brucellosis Vaccine Product Models, Descriptions and Specifications
12.7.4 Shchelkovo Biocombinat Live Brucellosis Vaccine Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.7.5 Shchelkovo Biocombinat Recent Developments
12.8 Jinyu Baoling
12.8.1 Jinyu Baoling Corporation Information
12.8.2 Jinyu Baoling Business Overview
12.8.3 Jinyu Baoling Live Brucellosis Vaccine Product Models, Descriptions and Specifications
12.8.4 Jinyu Baoling Live Brucellosis Vaccine Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.8.5 Jinyu Baoling Recent Developments
12.9 Biovet
12.9.1 Biovet Corporation Information
12.9.2 Biovet Business Overview
12.9.3 Biovet Live Brucellosis Vaccine Product Models, Descriptions and Specifications
12.9.4 Biovet Live Brucellosis Vaccine Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.9.5 Biovet Recent Developments
12.10 CAVAC
12.10.1 CAVAC Corporation Information
12.10.2 CAVAC Business Overview
12.10.3 CAVAC Live Brucellosis Vaccine Product Models, Descriptions and Specifications
12.10.4 CAVAC Live Brucellosis Vaccine Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.10.5 CAVAC Recent Developments
12.11 VETAL
12.11.1 VETAL Corporation Information
12.11.2 VETAL Business Overview
12.11.3 VETAL Live Brucellosis Vaccine Product Models, Descriptions and Specifications
12.11.4 VETAL Live Brucellosis Vaccine Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.11.5 VETAL Recent Developments
12.12 Indian Immunologicals
12.12.1 Indian Immunologicals Corporation Information
12.12.2 Indian Immunologicals Business Overview
12.12.3 Indian Immunologicals Live Brucellosis Vaccine Product Models, Descriptions and Specifications
12.12.4 Indian Immunologicals Live Brucellosis Vaccine Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.12.5 Indian Immunologicals Recent Developments
12.13 Dollvet
12.13.1 Dollvet Corporation Information
12.13.2 Dollvet Business Overview
12.13.3 Dollvet Live Brucellosis Vaccine Product Models, Descriptions and Specifications
12.13.4 Dollvet Live Brucellosis Vaccine Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.13.5 Dollvet Recent Developments
12.14 Hester Biosciences
12.14.1 Hester Biosciences Corporation Information
12.14.2 Hester Biosciences Business Overview
12.14.3 Hester Biosciences Live Brucellosis Vaccine Product Models, Descriptions and Specifications
12.14.4 Hester Biosciences Live Brucellosis Vaccine Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.14.5 Hester Biosciences Recent Developments
12.15 Qilu Animal Health
12.15.1 Qilu Animal Health Corporation Information
12.15.2 Qilu Animal Health Business Overview
12.15.3 Qilu Animal Health Live Brucellosis Vaccine Product Models, Descriptions and Specifications
12.15.4 Qilu Animal Health Live Brucellosis Vaccine Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.15.5 Qilu Animal Health Recent Developments
12.16 Auleon Biologicals
12.16.1 Auleon Biologicals Corporation Information
12.16.2 Auleon Biologicals Business Overview
12.16.3 Auleon Biologicals Live Brucellosis Vaccine Product Models, Descriptions and Specifications
12.16.4 Auleon Biologicals Live Brucellosis Vaccine Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.16.5 Auleon Biologicals Recent Developments
13 Value Chain and Supply-Chain Analysis
13.1 Live Brucellosis Vaccine Industry Chain
13.2 Live Brucellosis Vaccine Upstream Materials Analysis
13.2.1 Raw Materials
13.2.2 Key Suppliers Market Share & Risk Assessment
13.3 Live Brucellosis Vaccine Integrated Production Analysis
13.3.1 Manufacturing Footprint Analysis
13.3.2 Production Technology Overview
13.3.3 Regional Cost Drivers
13.4 Live Brucellosis Vaccine Sales Channels and Distribution Networks
13.4.1 Sales Channels
13.4.2 Distributors
14 Live Brucellosis Vaccine Market Dynamics
14.1 Industry Trends and Evolution
14.2 Market Growth Drivers and Emerging Opportunities
14.3 Market Challenges, Risks, and Restraints
15 Key Findings in the Global Live Brucellosis Vaccine Study
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.1.1 Research Programs/Design
16.1.1.2 Market Size Estimation
16.1.1.3 Market Breakdown and Data Triangulation
16.1.2 Data Source
16.1.2.1 Secondary Sources
16.1.2.2 Primary Sources
16.2 Author Details
List of Tables
Table 1. Global Live Brucellosis Vaccine Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Live Brucellosis Vaccine Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Live Brucellosis Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Live Brucellosis Vaccine Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Live Brucellosis Vaccine Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Live Brucellosis Vaccine Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Live Brucellosis Vaccine Sales by Region (2020-2025) & (K Units)
Table 8. Global Live Brucellosis Vaccine Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Live Brucellosis Vaccine Production Growth Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 11. Global Live Brucellosis Vaccine Production by Region (2020-2025) & (K Units)
Table 12. Global Live Brucellosis Vaccine Production by Region (2026-2031) & (K Units)
Table 13. Global Live Brucellosis Vaccine Sales by Manufacturers (2020-2025) & (K Units)
Table 14. Global Live Brucellosis Vaccine Sales Share by Manufacturers (2020-2025)
Table 15. Global Live Brucellosis Vaccine Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 16. Global Live Brucellosis Vaccine Revenue Market Share by Manufacturers (2020-2025)
Table 17. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 18. Global Live Brucellosis Vaccine by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Live Brucellosis Vaccine as of 2024)
Table 19. Global Live Brucellosis Vaccine Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 20. Global Live Brucellosis Vaccine Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 21. Key Manufacturers Live Brucellosis Vaccine Manufacturing Base and Headquarters
Table 22. Global Live Brucellosis Vaccine Market Concentration Ratio (CR5 and HHI)
Table 23. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 24. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 25. Global Live Brucellosis Vaccine Sales by Type (2020-2025) & (K Units)
Table 26. Global Live Brucellosis Vaccine Sales by Type (2026-2031) & (K Units)
Table 27. Global Live Brucellosis Vaccine Revenue by Type (2020-2025) & (US$ Million)
Table 28. Global Live Brucellosis Vaccine Revenue by Type (2026-2031) & (US$ Million)
Table 29. Global Live Brucellosis Vaccine ASP by Type (2020-2031) & (US$/Unit)
Table 30. Technical Specifications by Key Product Type
Table 31. Global Live Brucellosis Vaccine Sales by Application (2020-2025) & (K Units)
Table 32. Global Live Brucellosis Vaccine Sales by Application (2026-2031) & (K Units)
Table 33. Live Brucellosis Vaccine High-Growth Sectors Demand CAGR (2024-2031)
Table 34. Global Live Brucellosis Vaccine Revenue by Application (2020-2025) & (US$ Million)
Table 35. Global Live Brucellosis Vaccine Revenue by Application (2026-2031) & (US$ Million)
Table 36. Global Live Brucellosis Vaccine ASP by Application (2020-2031) & (US$/Unit)
Table 37. Top Customers by Region
Table 38. Top Customers by Application
Table 39. North America Live Brucellosis Vaccine Growth Accelerators and Market Barriers
Table 40. North America Live Brucellosis Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 41. North America Live Brucellosis Vaccine Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Europe Live Brucellosis Vaccine Growth Accelerators and Market Barriers
Table 43. Europe Live Brucellosis Vaccine Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 44. Europe Live Brucellosis Vaccine Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 45. Asia-Pacific Live Brucellosis Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Asia-Pacific Live Brucellosis Vaccine Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 47. Asia-Pacific Live Brucellosis Vaccine Growth Accelerators and Market Barriers
Table 48. Southeast Asia Live Brucellosis Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 49. Central and South America Live Brucellosis Vaccine Investment Opportunities and Key Challenges
Table 50. Central and South America Live Brucellosis Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 51. Middle East and Africa Live Brucellosis Vaccine Investment Opportunities and Key Challenges
Table 52. Middle East and Africa Live Brucellosis Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 53. CZ Vaccines Corporation Information
Table 54. CZ Vaccines Description and Major Businesses
Table 55. CZ Vaccines Product Models, Descriptions and Specifications
Table 56. CZ Vaccines Capacity, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 57. CZ Vaccines Sales Value Proportion by Product in 2024
Table 58. CZ Vaccines Sales Value Proportion by Application in 2024
Table 59. CZ Vaccines Sales Value Proportion by Geographic Area in 2024
Table 60. CZ Vaccines Live Brucellosis Vaccine SWOT Analysis
Table 61. CZ Vaccines Recent Developments
Table 62. MSD Corporation Information
Table 63. MSD Description and Major Businesses
Table 64. MSD Product Models, Descriptions and Specifications
Table 65. MSD Capacity, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 66. MSD Sales Value Proportion by Product in 2024
Table 67. MSD Sales Value Proportion by Application in 2024
Table 68. MSD Sales Value Proportion by Geographic Area in 2024
Table 69. MSD Live Brucellosis Vaccine SWOT Analysis
Table 70. MSD Recent Developments
Table 71. Ceva Corporation Information
Table 72. Ceva Description and Major Businesses
Table 73. Ceva Product Models, Descriptions and Specifications
Table 74. Ceva Capacity, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 75. Ceva Sales Value Proportion by Product in 2024
Table 76. Ceva Sales Value Proportion by Application in 2024
Table 77. Ceva Sales Value Proportion by Geographic Area in 2024
Table 78. Ceva Live Brucellosis Vaccine SWOT Analysis
Table 79. Ceva Recent Developments
Table 80. Colorado Serum Corporation Information
Table 81. Colorado Serum Description and Major Businesses
Table 82. Colorado Serum Product Models, Descriptions and Specifications
Table 83. Colorado Serum Capacity, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 84. Colorado Serum Sales Value Proportion by Product in 2024
Table 85. Colorado Serum Sales Value Proportion by Application in 2024
Table 86. Colorado Serum Sales Value Proportion by Geographic Area in 2024
Table 87. Colorado Serum Live Brucellosis Vaccine SWOT Analysis
Table 88. Colorado Serum Recent Developments
Table 89. Tecnovax Corporation Information
Table 90. Tecnovax Description and Major Businesses
Table 91. Tecnovax Product Models, Descriptions and Specifications
Table 92. Tecnovax Capacity, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Tecnovax Sales Value Proportion by Product in 2024
Table 94. Tecnovax Sales Value Proportion by Application in 2024
Table 95. Tecnovax Sales Value Proportion by Geographic Area in 2024
Table 96. Tecnovax Live Brucellosis Vaccine SWOT Analysis
Table 97. Tecnovax Recent Developments
Table 98. Syva Corporation Information
Table 99. Syva Description and Major Businesses
Table 100. Syva Product Models, Descriptions and Specifications
Table 101. Syva Capacity, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 102. Syva Recent Developments
Table 103. Shchelkovo Biocombinat Corporation Information
Table 104. Shchelkovo Biocombinat Description and Major Businesses
Table 105. Shchelkovo Biocombinat Product Models, Descriptions and Specifications
Table 106. Shchelkovo Biocombinat Capacity, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 107. Shchelkovo Biocombinat Recent Developments
Table 108. Jinyu Baoling Corporation Information
Table 109. Jinyu Baoling Description and Major Businesses
Table 110. Jinyu Baoling Product Models, Descriptions and Specifications
Table 111. Jinyu Baoling Capacity, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 112. Jinyu Baoling Recent Developments
Table 113. Biovet Corporation Information
Table 114. Biovet Description and Major Businesses
Table 115. Biovet Product Models, Descriptions and Specifications
Table 116. Biovet Capacity, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 117. Biovet Recent Developments
Table 118. CAVAC Corporation Information
Table 119. CAVAC Description and Major Businesses
Table 120. CAVAC Product Models, Descriptions and Specifications
Table 121. CAVAC Capacity, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 122. CAVAC Recent Developments
Table 123. VETAL Corporation Information
Table 124. VETAL Description and Major Businesses
Table 125. VETAL Product Models, Descriptions and Specifications
Table 126. VETAL Capacity, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 127. VETAL Recent Developments
Table 128. Indian Immunologicals Corporation Information
Table 129. Indian Immunologicals Description and Major Businesses
Table 130. Indian Immunologicals Product Models, Descriptions and Specifications
Table 131. Indian Immunologicals Capacity, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 132. Indian Immunologicals Recent Developments
Table 133. Dollvet Corporation Information
Table 134. Dollvet Description and Major Businesses
Table 135. Dollvet Product Models, Descriptions and Specifications
Table 136. Dollvet Capacity, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 137. Dollvet Recent Developments
Table 138. Hester Biosciences Corporation Information
Table 139. Hester Biosciences Description and Major Businesses
Table 140. Hester Biosciences Product Models, Descriptions and Specifications
Table 141. Hester Biosciences Capacity, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 142. Hester Biosciences Recent Developments
Table 143. Qilu Animal Health Corporation Information
Table 144. Qilu Animal Health Description and Major Businesses
Table 145. Qilu Animal Health Product Models, Descriptions and Specifications
Table 146. Qilu Animal Health Capacity, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 147. Qilu Animal Health Recent Developments
Table 148. Auleon Biologicals Corporation Information
Table 149. Auleon Biologicals Description and Major Businesses
Table 150. Auleon Biologicals Product Models, Descriptions and Specifications
Table 151. Auleon Biologicals Capacity, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 152. Auleon Biologicals Recent Developments
Table 153. Key Raw Materials Distribution
Table 154. Raw Materials Key Suppliers
Table 155. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 156. Milestones in Production Technology Evolution
Table 157. Distributors List
Table 158. Market Trends and Market Evolution
Table 159. Market Drivers and Opportunities
Table 160. Market Challenges, Risks, and Restraints
Table 161. Research Programs/Design for This Report
Table 162. Key Data Information from Secondary Sources
Table 163. Key Data Information from Primary Sources
List of Figures
Figure 1. Live Brucellosis Vaccine Product Picture
Figure 2. Global Live Brucellosis Vaccine Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Strain RB-51 Product Picture
Figure 4. Strain S19 Product Picture
Figure 5. Strain S2 Product Picture
Figure 6. Strain A19 Product Picture
Figure 7. Strain Rev. I Product Picture
Figure 8. Global Live Brucellosis Vaccine Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 9. Cattle
Figure 10. Sheep
Figure 11. Pig
Figure 12. Others
Figure 13. Live Brucellosis Vaccine Report Years Considered
Figure 14. Global Live Brucellosis Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Live Brucellosis Vaccine Revenue (2020-2031) & (US$ Million)
Figure 16. Global Live Brucellosis Vaccine Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 17. Global Live Brucellosis Vaccine Revenue Market Share by Region (2020-2031)
Figure 18. Global Live Brucellosis Vaccine Sales (2020-2031) & (K Units)
Figure 19. Global Live Brucellosis Vaccine Sales (CAGR) by Region (2020-2031) (K Units)
Figure 20. Global Live Brucellosis Vaccine Sales Market Share by Region (2020-2031)
Figure 21. Global Live Brucellosis Vaccine Capacity, Production and Utilization (2020-2031) & (K Units)
Figure 22. Global Live Brucellosis Vaccine Production Trend by Region (2020-2031) (K Units)
Figure 23. Global Live Brucellosis Vaccine Production Market Share by Region (2020-2031)
Figure 24. Production Capacity Enablers & Constraints
Figure 25. Live Brucellosis Vaccine Production Growth Rate in North America (2020-2031) & (K Units)
Figure 26. Live Brucellosis Vaccine Production Growth Rate in Europe (2020-2031) & (K Units)
Figure 27. Live Brucellosis Vaccine Production Growth Rate in China (2020-2031) & (K Units)
Figure 28. Live Brucellosis Vaccine Production Growth Rate in Japan (2020-2031) & (K Units)
Figure 29. Top 5 and Top 10 Manufacturers Live Brucellosis Vaccine Sales Volume Market Share in 2024
Figure 30. Global Live Brucellosis Vaccine Revenue Market Share Ranking (2024)
Figure 31. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 32. Strain RB-51 Revenue Market Share by Manufacturer in 2024
Figure 33. Strain S19 Revenue Market Share by Manufacturer in 2024
Figure 34. Strain S2 Revenue Market Share by Manufacturer in 2024
Figure 35. Strain A19 Revenue Market Share by Manufacturer in 2024
Figure 36. Strain Rev. I Revenue Market Share by Manufacturer in 2024
Figure 37. Type Eight Revenue Market Share by Manufacturer in 2024
Figure 38. Type Nine Revenue Market Share by Manufacturer in 2024
Figure 39. Global Live Brucellosis Vaccine Sales Market Share by Type (2020-2031)
Figure 40. Global Live Brucellosis Vaccine Revenue Market Share by Type (2020-2031)
Figure 41. Global Live Brucellosis Vaccine Sales Market Share by Application (2020-2031)
Figure 42. Global Live Brucellosis Vaccine Revenue Market Share by Application (2020-2031)
Figure 43. North America Live Brucellosis Vaccine Sales YoY (2020-2031) & (K Units)
Figure 44. North America Live Brucellosis Vaccine Revenue YoY (2020-2031) & (US$ Million)
Figure 45. North America Top 5 Manufacturers Live Brucellosis Vaccine Sales Revenue (US$ Million) in 2024
Figure 46. North America Live Brucellosis Vaccine Sales Volume (K Units) by Type (2020- 2031)
Figure 47. North America Live Brucellosis Vaccine Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 48. North America Live Brucellosis Vaccine Sales Volume (K Units) by Application (2020-2031)
Figure 49. North America Live Brucellosis Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
Figure 50. US Live Brucellosis Vaccine Revenue (2020-2031) & (US$ Million)
Figure 51. Canada Live Brucellosis Vaccine Revenue (2020-2031) & (US$ Million)
Figure 52. Mexico Live Brucellosis Vaccine Revenue (2020-2031) & (US$ Million)
Figure 53. Europe Live Brucellosis Vaccine Sales YoY (2020-2031) & (K Units)
Figure 54. Europe Live Brucellosis Vaccine Revenue YoY (2020-2031) & (US$ Million)
Figure 55. Europe Top 5 Manufacturers Live Brucellosis Vaccine Sales Revenue (US$ Million) in 2024
Figure 56. Europe Live Brucellosis Vaccine Sales Volume (K Units) by Type (2020-2031)
Figure 57. Europe Live Brucellosis Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
Figure 58. Europe Live Brucellosis Vaccine Sales Volume (K Units) by Application (2020-2031)
Figure 59. Europe Live Brucellosis Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
Figure 60. Germany Live Brucellosis Vaccine Revenue (2020-2031) & (US$ Million)
Figure 61. France Live Brucellosis Vaccine Revenue (2020-2031) & (US$ Million)
Figure 62. U.K. Live Brucellosis Vaccine Revenue (2020-2031) & (US$ Million)
Figure 63. Italy Live Brucellosis Vaccine Revenue (2020-2031) & (US$ Million)
Figure 64. Russia Live Brucellosis Vaccine Revenue (2020-2031) & (US$ Million)
Figure 65. Asia-Pacific Live Brucellosis Vaccine Sales YoY (2020-2031) & (K Units)
Figure 66. Asia-Pacific Live Brucellosis Vaccine Revenue YoY (2020-2031) & (US$ Million)
Figure 67. Asia-Pacific Top 8 Manufacturers Live Brucellosis Vaccine Sales Revenue (US$ Million) in 2024
Figure 68. Asia-Pacific Live Brucellosis Vaccine Sales Volume (K Units) by Type (2020- 2031)
Figure 69. Asia-Pacific Live Brucellosis Vaccine Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 70. Asia-Pacific Live Brucellosis Vaccine Sales Volume (K Units) by Application (2020-2031)
Figure 71. Asia-Pacific Live Brucellosis Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
Figure 72. Indonesia Live Brucellosis Vaccine Revenue (2020-2031) & (US$ Million)
Figure 73. Japan Live Brucellosis Vaccine Revenue (2020-2031) & (US$ Million)
Figure 74. South Korea Live Brucellosis Vaccine Revenue (2020-2031) & (US$ Million)
Figure 75. China Taiwan Live Brucellosis Vaccine Revenue (2020-2031) & (US$ Million)
Figure 76. India Live Brucellosis Vaccine Revenue (2020-2031) & (US$ Million)
Figure 77. Central and South America Live Brucellosis Vaccine Sales YoY (2020-2031) & (K Units)
Figure 78. Central and South America Live Brucellosis Vaccine Revenue YoY (2020-2031) & (US$ Million)
Figure 79. Central and South America Top 5 Manufacturers Live Brucellosis Vaccine Sales Revenue (US$ Million) in 2024
Figure 80. Central and South America Live Brucellosis Vaccine Sales Volume (K Units) by Type (2021-2031)
Figure 81. Central and South America Live Brucellosis Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
Figure 82. Central and South America Live Brucellosis Vaccine Sales Volume (K Units) by Application (2020-2031)
Figure 83. Central and South America Live Brucellosis Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
Figure 84. Brazil Live Brucellosis Vaccine Revenue (2020-2025) & (US$ Million)
Figure 85. Argentina Live Brucellosis Vaccine Revenue (2020-2025) & (US$ Million)
Figure 86. Middle East, and Africa Live Brucellosis Vaccine Sales YoY (2020-2031) & (K Units)
Figure 87. Middle East and Africa Live Brucellosis Vaccine Revenue YoY (2020-2031) & (US$ Million)
Figure 88. Middle East and Africa Top 5 Manufacturers Live Brucellosis Vaccine Sales Revenue (US$ Million) in 2024
Figure 89. Middle East and Africa Live Brucellosis Vaccine Sales Volume (K Units) by Type (2021-2031)
Figure 90. South America Live Brucellosis Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
Figure 91. Middle East and Africa Live Brucellosis Vaccine Sales Volume (K Units) by Application (2020-2031)
Figure 92. Middle East and Africa Live Brucellosis Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
Figure 93. GCC Countries Live Brucellosis Vaccine Revenue (2020-2025) & (US$ Million)
Figure 94. Turkey Live Brucellosis Vaccine Revenue (2020-2025) & (US$ Million)
Figure 95. Egypt Live Brucellosis Vaccine Revenue (2020-2025) & (US$ Million)
Figure 96. South Africa Live Brucellosis Vaccine Revenue (2020-2025) & (US$ Million)
Figure 97. Live Brucellosis Vaccine Industry Chain Mapping
Figure 98. Regional Live Brucellosis Vaccine Manufacturing Base Distribution (%)
Figure 99. Live Brucellosis Vaccine Production Process
Figure 100. Regional Live Brucellosis Vaccine Production Cost Structure
Figure 101. Channels of Distribution (Direct Vs Distribution)
Figure 102. Bottom-up and Top-down Approaches for This Report
Figure 103. Data Triangulation
Figure 104. Key Executives Interviewed
Table 1. Global Live Brucellosis Vaccine Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Live Brucellosis Vaccine Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Live Brucellosis Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Live Brucellosis Vaccine Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Live Brucellosis Vaccine Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Live Brucellosis Vaccine Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Live Brucellosis Vaccine Sales by Region (2020-2025) & (K Units)
Table 8. Global Live Brucellosis Vaccine Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Live Brucellosis Vaccine Production Growth Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 11. Global Live Brucellosis Vaccine Production by Region (2020-2025) & (K Units)
Table 12. Global Live Brucellosis Vaccine Production by Region (2026-2031) & (K Units)
Table 13. Global Live Brucellosis Vaccine Sales by Manufacturers (2020-2025) & (K Units)
Table 14. Global Live Brucellosis Vaccine Sales Share by Manufacturers (2020-2025)
Table 15. Global Live Brucellosis Vaccine Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 16. Global Live Brucellosis Vaccine Revenue Market Share by Manufacturers (2020-2025)
Table 17. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 18. Global Live Brucellosis Vaccine by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Live Brucellosis Vaccine as of 2024)
Table 19. Global Live Brucellosis Vaccine Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 20. Global Live Brucellosis Vaccine Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 21. Key Manufacturers Live Brucellosis Vaccine Manufacturing Base and Headquarters
Table 22. Global Live Brucellosis Vaccine Market Concentration Ratio (CR5 and HHI)
Table 23. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 24. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 25. Global Live Brucellosis Vaccine Sales by Type (2020-2025) & (K Units)
Table 26. Global Live Brucellosis Vaccine Sales by Type (2026-2031) & (K Units)
Table 27. Global Live Brucellosis Vaccine Revenue by Type (2020-2025) & (US$ Million)
Table 28. Global Live Brucellosis Vaccine Revenue by Type (2026-2031) & (US$ Million)
Table 29. Global Live Brucellosis Vaccine ASP by Type (2020-2031) & (US$/Unit)
Table 30. Technical Specifications by Key Product Type
Table 31. Global Live Brucellosis Vaccine Sales by Application (2020-2025) & (K Units)
Table 32. Global Live Brucellosis Vaccine Sales by Application (2026-2031) & (K Units)
Table 33. Live Brucellosis Vaccine High-Growth Sectors Demand CAGR (2024-2031)
Table 34. Global Live Brucellosis Vaccine Revenue by Application (2020-2025) & (US$ Million)
Table 35. Global Live Brucellosis Vaccine Revenue by Application (2026-2031) & (US$ Million)
Table 36. Global Live Brucellosis Vaccine ASP by Application (2020-2031) & (US$/Unit)
Table 37. Top Customers by Region
Table 38. Top Customers by Application
Table 39. North America Live Brucellosis Vaccine Growth Accelerators and Market Barriers
Table 40. North America Live Brucellosis Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 41. North America Live Brucellosis Vaccine Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Europe Live Brucellosis Vaccine Growth Accelerators and Market Barriers
Table 43. Europe Live Brucellosis Vaccine Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 44. Europe Live Brucellosis Vaccine Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 45. Asia-Pacific Live Brucellosis Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Asia-Pacific Live Brucellosis Vaccine Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 47. Asia-Pacific Live Brucellosis Vaccine Growth Accelerators and Market Barriers
Table 48. Southeast Asia Live Brucellosis Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 49. Central and South America Live Brucellosis Vaccine Investment Opportunities and Key Challenges
Table 50. Central and South America Live Brucellosis Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 51. Middle East and Africa Live Brucellosis Vaccine Investment Opportunities and Key Challenges
Table 52. Middle East and Africa Live Brucellosis Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 53. CZ Vaccines Corporation Information
Table 54. CZ Vaccines Description and Major Businesses
Table 55. CZ Vaccines Product Models, Descriptions and Specifications
Table 56. CZ Vaccines Capacity, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 57. CZ Vaccines Sales Value Proportion by Product in 2024
Table 58. CZ Vaccines Sales Value Proportion by Application in 2024
Table 59. CZ Vaccines Sales Value Proportion by Geographic Area in 2024
Table 60. CZ Vaccines Live Brucellosis Vaccine SWOT Analysis
Table 61. CZ Vaccines Recent Developments
Table 62. MSD Corporation Information
Table 63. MSD Description and Major Businesses
Table 64. MSD Product Models, Descriptions and Specifications
Table 65. MSD Capacity, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 66. MSD Sales Value Proportion by Product in 2024
Table 67. MSD Sales Value Proportion by Application in 2024
Table 68. MSD Sales Value Proportion by Geographic Area in 2024
Table 69. MSD Live Brucellosis Vaccine SWOT Analysis
Table 70. MSD Recent Developments
Table 71. Ceva Corporation Information
Table 72. Ceva Description and Major Businesses
Table 73. Ceva Product Models, Descriptions and Specifications
Table 74. Ceva Capacity, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 75. Ceva Sales Value Proportion by Product in 2024
Table 76. Ceva Sales Value Proportion by Application in 2024
Table 77. Ceva Sales Value Proportion by Geographic Area in 2024
Table 78. Ceva Live Brucellosis Vaccine SWOT Analysis
Table 79. Ceva Recent Developments
Table 80. Colorado Serum Corporation Information
Table 81. Colorado Serum Description and Major Businesses
Table 82. Colorado Serum Product Models, Descriptions and Specifications
Table 83. Colorado Serum Capacity, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 84. Colorado Serum Sales Value Proportion by Product in 2024
Table 85. Colorado Serum Sales Value Proportion by Application in 2024
Table 86. Colorado Serum Sales Value Proportion by Geographic Area in 2024
Table 87. Colorado Serum Live Brucellosis Vaccine SWOT Analysis
Table 88. Colorado Serum Recent Developments
Table 89. Tecnovax Corporation Information
Table 90. Tecnovax Description and Major Businesses
Table 91. Tecnovax Product Models, Descriptions and Specifications
Table 92. Tecnovax Capacity, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Tecnovax Sales Value Proportion by Product in 2024
Table 94. Tecnovax Sales Value Proportion by Application in 2024
Table 95. Tecnovax Sales Value Proportion by Geographic Area in 2024
Table 96. Tecnovax Live Brucellosis Vaccine SWOT Analysis
Table 97. Tecnovax Recent Developments
Table 98. Syva Corporation Information
Table 99. Syva Description and Major Businesses
Table 100. Syva Product Models, Descriptions and Specifications
Table 101. Syva Capacity, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 102. Syva Recent Developments
Table 103. Shchelkovo Biocombinat Corporation Information
Table 104. Shchelkovo Biocombinat Description and Major Businesses
Table 105. Shchelkovo Biocombinat Product Models, Descriptions and Specifications
Table 106. Shchelkovo Biocombinat Capacity, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 107. Shchelkovo Biocombinat Recent Developments
Table 108. Jinyu Baoling Corporation Information
Table 109. Jinyu Baoling Description and Major Businesses
Table 110. Jinyu Baoling Product Models, Descriptions and Specifications
Table 111. Jinyu Baoling Capacity, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 112. Jinyu Baoling Recent Developments
Table 113. Biovet Corporation Information
Table 114. Biovet Description and Major Businesses
Table 115. Biovet Product Models, Descriptions and Specifications
Table 116. Biovet Capacity, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 117. Biovet Recent Developments
Table 118. CAVAC Corporation Information
Table 119. CAVAC Description and Major Businesses
Table 120. CAVAC Product Models, Descriptions and Specifications
Table 121. CAVAC Capacity, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 122. CAVAC Recent Developments
Table 123. VETAL Corporation Information
Table 124. VETAL Description and Major Businesses
Table 125. VETAL Product Models, Descriptions and Specifications
Table 126. VETAL Capacity, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 127. VETAL Recent Developments
Table 128. Indian Immunologicals Corporation Information
Table 129. Indian Immunologicals Description and Major Businesses
Table 130. Indian Immunologicals Product Models, Descriptions and Specifications
Table 131. Indian Immunologicals Capacity, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 132. Indian Immunologicals Recent Developments
Table 133. Dollvet Corporation Information
Table 134. Dollvet Description and Major Businesses
Table 135. Dollvet Product Models, Descriptions and Specifications
Table 136. Dollvet Capacity, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 137. Dollvet Recent Developments
Table 138. Hester Biosciences Corporation Information
Table 139. Hester Biosciences Description and Major Businesses
Table 140. Hester Biosciences Product Models, Descriptions and Specifications
Table 141. Hester Biosciences Capacity, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 142. Hester Biosciences Recent Developments
Table 143. Qilu Animal Health Corporation Information
Table 144. Qilu Animal Health Description and Major Businesses
Table 145. Qilu Animal Health Product Models, Descriptions and Specifications
Table 146. Qilu Animal Health Capacity, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 147. Qilu Animal Health Recent Developments
Table 148. Auleon Biologicals Corporation Information
Table 149. Auleon Biologicals Description and Major Businesses
Table 150. Auleon Biologicals Product Models, Descriptions and Specifications
Table 151. Auleon Biologicals Capacity, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 152. Auleon Biologicals Recent Developments
Table 153. Key Raw Materials Distribution
Table 154. Raw Materials Key Suppliers
Table 155. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 156. Milestones in Production Technology Evolution
Table 157. Distributors List
Table 158. Market Trends and Market Evolution
Table 159. Market Drivers and Opportunities
Table 160. Market Challenges, Risks, and Restraints
Table 161. Research Programs/Design for This Report
Table 162. Key Data Information from Secondary Sources
Table 163. Key Data Information from Primary Sources
List of Figures
Figure 1. Live Brucellosis Vaccine Product Picture
Figure 2. Global Live Brucellosis Vaccine Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Strain RB-51 Product Picture
Figure 4. Strain S19 Product Picture
Figure 5. Strain S2 Product Picture
Figure 6. Strain A19 Product Picture
Figure 7. Strain Rev. I Product Picture
Figure 8. Global Live Brucellosis Vaccine Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 9. Cattle
Figure 10. Sheep
Figure 11. Pig
Figure 12. Others
Figure 13. Live Brucellosis Vaccine Report Years Considered
Figure 14. Global Live Brucellosis Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Live Brucellosis Vaccine Revenue (2020-2031) & (US$ Million)
Figure 16. Global Live Brucellosis Vaccine Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 17. Global Live Brucellosis Vaccine Revenue Market Share by Region (2020-2031)
Figure 18. Global Live Brucellosis Vaccine Sales (2020-2031) & (K Units)
Figure 19. Global Live Brucellosis Vaccine Sales (CAGR) by Region (2020-2031) (K Units)
Figure 20. Global Live Brucellosis Vaccine Sales Market Share by Region (2020-2031)
Figure 21. Global Live Brucellosis Vaccine Capacity, Production and Utilization (2020-2031) & (K Units)
Figure 22. Global Live Brucellosis Vaccine Production Trend by Region (2020-2031) (K Units)
Figure 23. Global Live Brucellosis Vaccine Production Market Share by Region (2020-2031)
Figure 24. Production Capacity Enablers & Constraints
Figure 25. Live Brucellosis Vaccine Production Growth Rate in North America (2020-2031) & (K Units)
Figure 26. Live Brucellosis Vaccine Production Growth Rate in Europe (2020-2031) & (K Units)
Figure 27. Live Brucellosis Vaccine Production Growth Rate in China (2020-2031) & (K Units)
Figure 28. Live Brucellosis Vaccine Production Growth Rate in Japan (2020-2031) & (K Units)
Figure 29. Top 5 and Top 10 Manufacturers Live Brucellosis Vaccine Sales Volume Market Share in 2024
Figure 30. Global Live Brucellosis Vaccine Revenue Market Share Ranking (2024)
Figure 31. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 32. Strain RB-51 Revenue Market Share by Manufacturer in 2024
Figure 33. Strain S19 Revenue Market Share by Manufacturer in 2024
Figure 34. Strain S2 Revenue Market Share by Manufacturer in 2024
Figure 35. Strain A19 Revenue Market Share by Manufacturer in 2024
Figure 36. Strain Rev. I Revenue Market Share by Manufacturer in 2024
Figure 37. Type Eight Revenue Market Share by Manufacturer in 2024
Figure 38. Type Nine Revenue Market Share by Manufacturer in 2024
Figure 39. Global Live Brucellosis Vaccine Sales Market Share by Type (2020-2031)
Figure 40. Global Live Brucellosis Vaccine Revenue Market Share by Type (2020-2031)
Figure 41. Global Live Brucellosis Vaccine Sales Market Share by Application (2020-2031)
Figure 42. Global Live Brucellosis Vaccine Revenue Market Share by Application (2020-2031)
Figure 43. North America Live Brucellosis Vaccine Sales YoY (2020-2031) & (K Units)
Figure 44. North America Live Brucellosis Vaccine Revenue YoY (2020-2031) & (US$ Million)
Figure 45. North America Top 5 Manufacturers Live Brucellosis Vaccine Sales Revenue (US$ Million) in 2024
Figure 46. North America Live Brucellosis Vaccine Sales Volume (K Units) by Type (2020- 2031)
Figure 47. North America Live Brucellosis Vaccine Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 48. North America Live Brucellosis Vaccine Sales Volume (K Units) by Application (2020-2031)
Figure 49. North America Live Brucellosis Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
Figure 50. US Live Brucellosis Vaccine Revenue (2020-2031) & (US$ Million)
Figure 51. Canada Live Brucellosis Vaccine Revenue (2020-2031) & (US$ Million)
Figure 52. Mexico Live Brucellosis Vaccine Revenue (2020-2031) & (US$ Million)
Figure 53. Europe Live Brucellosis Vaccine Sales YoY (2020-2031) & (K Units)
Figure 54. Europe Live Brucellosis Vaccine Revenue YoY (2020-2031) & (US$ Million)
Figure 55. Europe Top 5 Manufacturers Live Brucellosis Vaccine Sales Revenue (US$ Million) in 2024
Figure 56. Europe Live Brucellosis Vaccine Sales Volume (K Units) by Type (2020-2031)
Figure 57. Europe Live Brucellosis Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
Figure 58. Europe Live Brucellosis Vaccine Sales Volume (K Units) by Application (2020-2031)
Figure 59. Europe Live Brucellosis Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
Figure 60. Germany Live Brucellosis Vaccine Revenue (2020-2031) & (US$ Million)
Figure 61. France Live Brucellosis Vaccine Revenue (2020-2031) & (US$ Million)
Figure 62. U.K. Live Brucellosis Vaccine Revenue (2020-2031) & (US$ Million)
Figure 63. Italy Live Brucellosis Vaccine Revenue (2020-2031) & (US$ Million)
Figure 64. Russia Live Brucellosis Vaccine Revenue (2020-2031) & (US$ Million)
Figure 65. Asia-Pacific Live Brucellosis Vaccine Sales YoY (2020-2031) & (K Units)
Figure 66. Asia-Pacific Live Brucellosis Vaccine Revenue YoY (2020-2031) & (US$ Million)
Figure 67. Asia-Pacific Top 8 Manufacturers Live Brucellosis Vaccine Sales Revenue (US$ Million) in 2024
Figure 68. Asia-Pacific Live Brucellosis Vaccine Sales Volume (K Units) by Type (2020- 2031)
Figure 69. Asia-Pacific Live Brucellosis Vaccine Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 70. Asia-Pacific Live Brucellosis Vaccine Sales Volume (K Units) by Application (2020-2031)
Figure 71. Asia-Pacific Live Brucellosis Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
Figure 72. Indonesia Live Brucellosis Vaccine Revenue (2020-2031) & (US$ Million)
Figure 73. Japan Live Brucellosis Vaccine Revenue (2020-2031) & (US$ Million)
Figure 74. South Korea Live Brucellosis Vaccine Revenue (2020-2031) & (US$ Million)
Figure 75. China Taiwan Live Brucellosis Vaccine Revenue (2020-2031) & (US$ Million)
Figure 76. India Live Brucellosis Vaccine Revenue (2020-2031) & (US$ Million)
Figure 77. Central and South America Live Brucellosis Vaccine Sales YoY (2020-2031) & (K Units)
Figure 78. Central and South America Live Brucellosis Vaccine Revenue YoY (2020-2031) & (US$ Million)
Figure 79. Central and South America Top 5 Manufacturers Live Brucellosis Vaccine Sales Revenue (US$ Million) in 2024
Figure 80. Central and South America Live Brucellosis Vaccine Sales Volume (K Units) by Type (2021-2031)
Figure 81. Central and South America Live Brucellosis Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
Figure 82. Central and South America Live Brucellosis Vaccine Sales Volume (K Units) by Application (2020-2031)
Figure 83. Central and South America Live Brucellosis Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
Figure 84. Brazil Live Brucellosis Vaccine Revenue (2020-2025) & (US$ Million)
Figure 85. Argentina Live Brucellosis Vaccine Revenue (2020-2025) & (US$ Million)
Figure 86. Middle East, and Africa Live Brucellosis Vaccine Sales YoY (2020-2031) & (K Units)
Figure 87. Middle East and Africa Live Brucellosis Vaccine Revenue YoY (2020-2031) & (US$ Million)
Figure 88. Middle East and Africa Top 5 Manufacturers Live Brucellosis Vaccine Sales Revenue (US$ Million) in 2024
Figure 89. Middle East and Africa Live Brucellosis Vaccine Sales Volume (K Units) by Type (2021-2031)
Figure 90. South America Live Brucellosis Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
Figure 91. Middle East and Africa Live Brucellosis Vaccine Sales Volume (K Units) by Application (2020-2031)
Figure 92. Middle East and Africa Live Brucellosis Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
Figure 93. GCC Countries Live Brucellosis Vaccine Revenue (2020-2025) & (US$ Million)
Figure 94. Turkey Live Brucellosis Vaccine Revenue (2020-2025) & (US$ Million)
Figure 95. Egypt Live Brucellosis Vaccine Revenue (2020-2025) & (US$ Million)
Figure 96. South Africa Live Brucellosis Vaccine Revenue (2020-2025) & (US$ Million)
Figure 97. Live Brucellosis Vaccine Industry Chain Mapping
Figure 98. Regional Live Brucellosis Vaccine Manufacturing Base Distribution (%)
Figure 99. Live Brucellosis Vaccine Production Process
Figure 100. Regional Live Brucellosis Vaccine Production Cost Structure
Figure 101. Channels of Distribution (Direct Vs Distribution)
Figure 102. Bottom-up and Top-down Approaches for This Report
Figure 103. Data Triangulation
Figure 104. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Spatial Metabolomics Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 04, 25
Global Pharmaceutical Process Analytical Technology (PAT) Software Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 04, 25
Global HASE Rheology Modifiers Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 04, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232